The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population

Table 1

Demographic and clinicopathological characteristics of PTC and CPTC patients.

BRAF V600E status	PTC			CPTC
	BRAF V600E-positive	BRAF V600E-negative		BRAF V600E-positive	BRAF V600E-negative	value
Number of patients	1102 (87.7%)	155 (12.3%)		1081(90.1%)	119 (9.9%)
Sex			0.088			0.162
Male	314 (28.5%)	34 (21.9%)		311 (28.8%)	27 (22.7%)
Female	788 (71.5%)	121 (78.1%)		770 (71.2%)	92 (77.3%)
Age (years)	43 [33–53]	37 [29–49]	<0.001	43 [33–53]	37 [29–49]	<0.001
≥45 y	517 (46.9%)	51 (32.9%)	0.001	503 (46.5%)	41 (34.5%)	0.012
Subtype			<0.001			—
CPTC	1081 (98.1%)	119 (76.8%)		—	—
FVPTC	11 (1.0%)	25 (16.1%)		—	—
Other	10 (0.9%)	11 (7.1%)		—	—
Tumor size (cm)	1.0 [0.7–1.5]	1.0 [0.8–1.8]	0.174	1.0 [0.7–1.5]	1.0 [0.7–1.5]	0.649
>1 cm	466 (42.3%)	71 (45.8%)	0.407	458 (42.4%)	50 (42.0%)	0.941
Multifocality	396 (35.9%)	37 (23.9%)	0.003	390 (36.1%)	31 (26.1%)	0.030
ETE	568 (51.5%)	68 (43.9%)	0.074	556 (51.4%)	51 (42.9%)	0.076
Central LNM	556 (50.5%)	81 (52.3%)	0.674	550 (50.9%)	66 (55.5%)	0.342
Lateral LNM	185 (16.8%)	38 (24.5%)	0.018	181 (16.7%)	28 (23.5%)	0.064
Hashimoto’s thyroiditis	281 (25.5%)	62 (40.0%)	<0.001	269 (24.9%)	49 (41.2%)	<0.001
Distant metastasis	15 (1.4%)	4 (2.6%)	0.279	15 (1.4%)	2 (1.7%)	0.682
TNM stage			0.011			0.020
I	717 (65.1%)	116 (74.8%)		706 (65.3%)	90 (75.6%)
II	11 (1.0%)	5 (3.2%)		9 (0.8%)	3 (2.5%)
III	281 (25.5%)	25 (16.1%)		275 (25.4%)	19 (16.0%)
IV	93 (8.4%)	9 (5.8%)		91 (8.4%)	7 (5.9%)
Follow-up time (months)	21 [15–29]	21 [15–30]	0.310	21 [15–29]	22.5 [17–32]	0.030

Data were from 1167 patients who had follow-up data.